Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Dermatology

Expert Opinion / Conference Coverage · September 26, 2013

8 Changes I Made in My Clinical Practice in 2013

 

Additional Info

  1. McKay KM, Sambrano BL, Fox PS, et al. Thickness of superficial basal cell carcinoma (sBCC) predicts imiquimod efficacy: a proposal for a thickness-based definition of sBCC. Br J Dermatol. 2013 Sep;169(3):549-54.

  2. Butala N, Siegfried E, Weissler A. Molluscum BOTE sign: a predictor of imminent resolution. Pediatrics. 2013 May;131(5):e1650-3. doi: 10.1542/peds.2012-2933. Epub 2013 Apr 1.

  3. Bakker CV, Terra JB, Pas HH, Jonkman MF. Bullous pemphigoid as pruritus in the elderly: a common presentation. JAMA Dermatol. 2013 Aug 1;149(8):950-3. doi: 10.1001/jamadermatol.2013.756.

  4. Joly P, C Benoit-Corven, S Baricault, et al. Associated with Chronic Exposure to Calcium Channel Blockers: Results from a Case–Control Study. Journal of Investigative Dermatology (2007) 127, 2766–2771.

  5. Melinda B Chu, Garrett Searcy, Elaine Siegfried. CASE REPORT: Efficacy of topical brimonidine-timolol for haemangioma of infancy and perils of off-label prescribing. BMJ Case Reports 2013.

  6. Wu W, Robinson-Bostom L, Kokkotou E, et al. Dyslipidemia in granuloma annulare: a case-control study. Arch Dermatol. 2012 Oct;148(10):1131-6.

  7. Aleksandar Sekulic, Michael R. Migden, Anthony E. Oro, et al. Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma. N Engl J Med 2012; 366:2171-2179.

Disclosure statements are available on the authors' profiles:

Further Reading